Signaturefd LLC raised its position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 4.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 59,192 shares of the company’s stock after purchasing an additional 2,565 shares during the period. Signaturefd LLC’s holdings in AbbVie were worth $15,484,000 as of its most recent SEC filing.
Several other institutional investors have also made changes to their positions in ABBV. State Street Corp raised its position in AbbVie by 1.7% during the second quarter. State Street Corp now owns 82,596,748 shares of the company’s stock valued at $20,784,646,000 after acquiring an additional 1,379,232 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in AbbVie by 0.7% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock valued at $3,590,323,000 after acquiring an additional 106,091 shares during the last quarter. Legal & General Group Plc bought a new stake in AbbVie in the second quarter worth approximately $2,905,952,000. Deutsche Bank AG grew its position in AbbVie by 13.0% in the second quarter. Deutsche Bank AG now owns 10,772,949 shares of the company’s stock worth $2,710,905,000 after acquiring an additional 1,241,587 shares in the last quarter. Finally, Amundi increased its stake in shares of AbbVie by 2.4% during the 1st quarter. Amundi now owns 10,698,095 shares of the company’s stock worth $2,326,728,000 after purchasing an additional 247,689 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.
AbbVie News Roundup
Here are the key news stories impacting AbbVie this week:
- Positive Sentiment: The U.S. FDA approved a subcutaneous induction regimen for SKYRIZI in adults with moderately to severely active Crohn’s disease. The on-body injector provides a more convenient administration option throughout treatment, while Phase 3 data showed superior clinical remission and endoscopic response versus placebo with no new safety risks. The approval could strengthen SKYRIZI’s commercial position and support AbbVie’s post-Humira growth strategy. FDA approves subcutaneous SKYRIZI induction for Crohn’s disease
- Positive Sentiment: AbbVie’s dividend remains a key defensive attraction. Analysts and financial commentators point to the company’s ability to maintain shareholder payouts despite Humira’s patent loss, supported by growth from SKYRIZI, RINVOQ and other newer products. AbbVie’s dividend after Humira’s patent cliff
- Neutral Sentiment: AbbVie’s Phase 3 INTREPID trial for lutikizumab in hidradenitis suppurativa met its primary endpoint and eight ranked secondary endpoints, including reduced pain and fewer flares. However, reported efficacy was viewed by some analysts as underwhelming relative to competing treatments, leaving the drug’s eventual commercial opportunity uncertain. AbbVie reports Phase 3 INTREPID results for lutikizumab
- Negative Sentiment: Investors are approaching next week’s earnings report cautiously. Erste Group lowered its 2026 EPS estimate to $13.90 from $14.00, slightly below the roughly $13.94 consensus, while a Zacks preview said AbbVie lacks the usual indicators for a likely earnings beat. With the shares trading near their 52-week high and at a premium valuation, results and guidance may need to be strong to sustain momentum. AbbVie earnings preview
AbbVie Stock Performance
NYSE:ABBV opened at $285.66 on Monday. The company has a 50-day moving average of $266.33 and a 200-day moving average of $242.01. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $291.40. The company has a market capitalization of $504.70 billion, a price-to-earnings ratio of 80.69, a PEG ratio of 1.30 and a beta of 0.24.
AbbVie (NYSE:ABBV – Get Free Report) last posted its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business had revenue of $16.99 billion for the quarter, compared to analysts’ expectations of $16.80 billion. During the same quarter in the previous year, the firm posted $2.97 earnings per share. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Sell-side analysts forecast that AbbVie Inc. will post 13.93 EPS for the current year.
AbbVie Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s payout ratio is presently 195.48%.
Analysts Set New Price Targets
A number of research analysts have recently weighed in on ABBV shares. Argus raised their price target on shares of AbbVie from $250.00 to $270.00 in a report on Tuesday, August 4th. Wolfe Research raised shares of AbbVie from a “peer perform” rating to an “outperform” rating and lifted their price objective for the company from $235.00 to $300.00 in a research note on Thursday, August 13th. Oppenheimer upped their price objective on shares of AbbVie from $244.00 to $258.00 and gave the stock a “neutral” rating in a report on Monday, August 3rd. Rothschild & Co Redburn increased their target price on shares of AbbVie from $284.00 to $285.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Finally, HSBC raised their target price on AbbVie from $300.00 to $315.00 and gave the company a “buy” rating in a report on Thursday, September 10th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $279.86.
Check Out Our Latest Research Report on ABBV
Insider Buying and Selling at AbbVie
In other news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. This represents a 30.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 0.06% of the company’s stock.
About AbbVie
AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.
The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.
Read More
- Five stocks we like better than AbbVie
- Newmont’s Record Quarter Shows Why Gold’s Floor Is the Real Story
- Albemarle Upgrade: Can Energy Storage Recharge Lithium’s Leader?
- Consumer Staples Are Up 12% This Year—These 3 Beverage Stocks Are Leading the Way
- Can Planet Fitness Get Its Growth Back in Shape?
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
